← board
MRMD
distress 3/10 · well-funded / low risk$0.070%today-64% from 52w high
Revenue
$39M
Liquidity
$8M
Runway
—
Shares 1y
+2%
Price & events
-30.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-1.5%
1W
-1.5%
1M
-19.8%
3M
-30.9%
6M
-39.3%
1Y
-61.8%
2Y
-92.9%
5Y
-87.1%
All
Overview
- Market Cap
- $25.95M
- Enterprise Value
- $100.56M
- Volume
- 149.00K
- 52 Week Range
- $0.07 – $0.18
- Total Shares
- 399.27M
- Float Shares
- 331.83M
- % Held by Insiders
- 14.50%
- % Held by Institutions
- 0.24%
- RVOL
- 0.41x
- Beta
- 1.33
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 399,266,091 · 0 offerings/1y · 1 PIPEs
- 2026-03-028-Kprivate_placement
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $ · analysts
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-18Form 4 Marimed Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17MariMed (MRMD) director awarded 192,308 RSUs converting to shares - Stock Titan
- 2026-07-15MariMed to report Q2 2026 earnings on August 12 - scanx.trade
- 2026-07-15MariMed Announces Second Quarter 2026 Earnings Date - Yahoo Finance
- 2026-07-15MariMed (MRMD) Schedules Q2 2026 Earnings Release for August 12 with Management Call on August 13 - Kalkine Media
- 2026-07-14MariMed’s Betty’s Eddies™ Expands Core Lineup with New Multi-Vitamin Inspired Betty's Bite-A-Mins - GlobeNewswire
- 2026-07-14MariMed’s Betty’s Eddies™ Expands Core Lineup with New Multi-Vitamin Inspired Betty's Bite-A-Mins - Yahoo Finance
- 2026-07-08MariMed’s Nature’s Heritage Launches ‘The Nose Knows’ Immersive, Science-Backed Consumer Education Campaign - Cannabis Business Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.